This content is for informational purposes only and does not constitute medical advice. Statements about dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary — consult your healthcare provider before starting any supplement. Full disclaimer
A 2021 meta-analysis of 6 randomized controlled trials (371 participants) found coenzyme Q10 (CoQ10) was associated...
A 2021 meta-analysis of 6 randomized controlled trials (371 participants) found coenzyme Q10 (CoQ10) was associated with a reduction of about 1.5 migraine attacks per month versus control, along with shorter attack duration. It did not significantly reduce attack severity, and certainty was limited by the small number of trials. CoQ10 is studied as a preventive option to discuss with a clinician.
| Study | Participants | Finding | Quality |
|---|---|---|---|
Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine—a meta-analysis Sazali S, Badrin S, Norhayati MN, Idris NS — BMJ Open (2021) | 371 | CoQ10 was associated with ~1.52 fewer migraine attacks per month and shorter duration vs control; attack severity was not significantly reduced. | Moderate |
Coenzyme Q10 has been studied for supporting fewer migraine days, with meta-analysis linking it to about 1.5 fewer attacks per month — a modest preventive effect, with no clear effect on how severe attacks are. Studied doses ranged widely (commonly around 300 mg/day, sometimes split). Because the evidence base is small, CoQ10 is best viewed as a possible add-on to discuss with a clinician as part of a migraine plan, not a standalone fix. This is supportive information, not medical advice; new, severe, or changing headaches warrant medical evaluation.
A meta-analysis of randomized trials found coenzyme Q10 was associated with fewer monthly migraine attacks, though it did not significantly reduce attack severity.
A meta-analysis found CoQ10 was associated with about 1.5 fewer migraine attacks per month and shorter attacks, though it did not clearly reduce how severe attacks were. It is studied as a preventive (prophylactic) option, not a treatment for an attack in progress.
Doses across trials ranged widely (about 30–800 mg/day), with roughly 300 mg/day being a commonly used amount, sometimes split into multiple doses. A clinician can help choose an appropriate dose as part of a migraine plan.
Like most migraine preventives, CoQ10 is taken consistently over weeks to months rather than for acute relief. Give it a sustained trial and track your attack frequency, ideally with clinician guidance.
CoQ10 was generally well tolerated in the trials, with mainly mild digestive effects. As always, discuss it with your clinician if you take medications or have a health condition, and seek care for sudden severe or unusual headaches.
